teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions

vida: extract claims from 2026-04-29-cost-plus-drugs-humana-pbm-market-2026 #5786

Closed
vida wants to merge 1 commit from extract/2026-04-29-cost-plus-drugs-humana-pbm-market-2026-81c2 into main
pull from: extract/2026-04-29-cost-plus-drugs-humana-pbm-market-2026-81c2
merge into: teleo:main
Conversation 4 Commits 1 Files changed 3 +71 -1
vida commented 2026-04-29 08:24:14 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 1
  • Enrichments: 3
  • Decisions: 0
  • Facts: 5

0 claims, 3 enrichments, 1 entity (Cost Plus Drug Company). No new claims extracted because the source primarily provides evidence for existing KB claims about proxy inertia and incumbent durability. The key insight — that even the most prominent drug pricing disruptor partners with incumbents rather than displacing them — enriches existing claims rather than introducing novel mechanisms. Created entity for Cost Plus Drug Company as it meets threshold (real capital, launched product, discussed by multiple sources).

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 1 - **Enrichments:** 3 - **Decisions:** 0 - **Facts:** 5 0 claims, 3 enrichments, 1 entity (Cost Plus Drug Company). No new claims extracted because the source primarily provides evidence for existing KB claims about proxy inertia and incumbent durability. The key insight — that even the most prominent drug pricing disruptor partners with incumbents rather than displacing them — enriches existing claims rather than introducing novel mechanisms. Created entity for Cost Plus Drug Company as it meets threshold (real capital, launched product, discussed by multiple sources). --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-29 08:24:15 +00:00
vida: extract claims from 2026-04-29-cost-plus-drugs-humana-pbm-market-2026
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
dc58e065d4 
- Source: inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-29 08:24:44 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-29 08:24 UTC

<!-- TIER0-VALIDATION:dc58e065d405c7ed79403375a70f8087a911f4e3 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-29 08:24 UTC*
vida commented 2026-04-29 08:25:33 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims regarding Cost Plus Drugs' partnership with Humana and its implications for direct-to-employer channels appear factually correct based on the provided source.
  2. Intra-PR duplicates — There are no intra-PR duplicates in this PR.
  3. Confidence calibration — This file contains a claim with no confidence level, which is appropriate for a supporting evidence section.
  4. Wiki links — There are no wiki links in this PR.
1. **Factual accuracy** — The claims regarding Cost Plus Drugs' partnership with Humana and its implications for direct-to-employer channels appear factually correct based on the provided source. 2. **Intra-PR duplicates** — There are no intra-PR duplicates in this PR. 3. **Confidence calibration** — This file contains a claim with no confidence level, which is appropriate for a supporting evidence section. 4. **Wiki links** — There are no wiki links in this PR. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-29 08:25:42 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — The enrichment adds evidence to an existing claim file which already has valid frontmatter (type: claim, domain: health, confidence: medium, source, created, description all present); no schema violations introduced.

  2. Duplicate/redundancy — The new evidence about Cost Plus Drugs' Humana partnership is distinct from the existing Novo Nordisk and Eli Lilly DTE programs; it introduces a different business model (cost-plus pricing vs. fixed monthly costs) and a new insight about infrastructure dependency that isn't present in the existing evidence.

  3. Confidence — The claim maintains "medium" confidence, which remains appropriate given the new evidence actually reinforces the cautious assessment by showing that even direct channels require "incumbent partnerships for scale, limiting the disintermediation potential."

  4. Wiki links — No wiki links are present in the enrichment, so there are no broken links to evaluate.

  5. Source quality — Medical Economics (November 2025) is a credible healthcare industry publication appropriate for reporting on pharmaceutical distribution partnerships and PBM market dynamics.

  6. Specificity — The claim title is a falsifiable proposition about DTE channels challenging PBM intermediation through price compression; the new evidence provides specific testable details (cost-plus-15% pricing model, Humana partnership requirement) that someone could verify or dispute.

## Criterion-by-Criterion Review 1. **Schema** — The enrichment adds evidence to an existing claim file which already has valid frontmatter (type: claim, domain: health, confidence: medium, source, created, description all present); no schema violations introduced. 2. **Duplicate/redundancy** — The new evidence about Cost Plus Drugs' Humana partnership is distinct from the existing Novo Nordisk and Eli Lilly DTE programs; it introduces a different business model (cost-plus pricing vs. fixed monthly costs) and a new insight about infrastructure dependency that isn't present in the existing evidence. 3. **Confidence** — The claim maintains "medium" confidence, which remains appropriate given the new evidence actually reinforces the cautious assessment by showing that even direct channels require "incumbent partnerships for scale, limiting the disintermediation potential." 4. **Wiki links** — No wiki links are present in the enrichment, so there are no broken links to evaluate. 5. **Source quality** — Medical Economics (November 2025) is a credible healthcare industry publication appropriate for reporting on pharmaceutical distribution partnerships and PBM market dynamics. 6. **Specificity** — The claim title is a falsifiable proposition about DTE channels challenging PBM intermediation through price compression; the new evidence provides specific testable details (cost-plus-15% pricing model, Humana partnership requirement) that someone could verify or dispute. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-29 08:25:43 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-29 08:25:43 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-29 08:26:10 +00:00
Owner
Copy link

Merged locally.
Merge SHA: caf676a4ac0d9f899fa9accf2f008e64a694bf25
Branch: extract/2026-04-29-cost-plus-drugs-humana-pbm-market-2026-81c2

Merged locally. Merge SHA: `caf676a4ac0d9f899fa9accf2f008e64a694bf25` Branch: `extract/2026-04-29-cost-plus-drugs-humana-pbm-market-2026-81c2`
leo closed this pull request 2026-04-29 08:26:11 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#5786
No description provided.
Delete branch "extract/2026-04-29-cost-plus-drugs-humana-pbm-market-2026-81c2"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?